US drugs giant Merck & Co (NYSE: MRK) says that, after nearly 40 years with the group, its chairman, Richard Clark, will retire from the company and the Merck board of directors effective December 1, and that Kenneth Frazier has been elected to replace him in this post.
Mr Clark led the company for five years as president and chief executive officer from 2005 through 2010. He has served as a Merck director since May 2005 and chairman of its board of directors since 2007. In January 2011, Mr Frazier became Merck's president and chief executive and a member of its board, positions he will retain.
Merck credits Mr Clark with leading its $41 billion acquisition of fellow US drug major Schering-Plough in November 2009. The deal expanded Merck's pipeline and gave it more biotechnology and consumer health products. It also made Merck the world’s second-largest pharmaceutical company in terms of revenue, behind Pfizer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze